SUPPLEMENTARY MATERIAL

Effectiveness of phyto-active molecules on transcriptional expression, biofilm matrix and cell wall components of *Candida glabrata* and its clinical isolates

Payal Gupta[1], Sonam Gupta[1], Meenakshi Sharma[1], Navin Kumar[2], Vikas Pruthi[1*], Krishna Mohan Poluri[1*]

[1]Department of Biotechnology, Indian Institute of Technology Roorkee,

Roorkee - 247667, Uttarakhand, India

[2]Department of Biotechnology, Graphic Era University, Dehradun - 248002, Uttarakhand, India

Corresponding Authors:

Prof. VikasPruthi
Email: vikasfbs@iitr.ac.in;vikasfbs@gmail.com
PH.: 091-1332-285530
Fax: 091-1332-273560

Dr. Krishna Mohan Poluri
Email: mohanpmk@gmail.com; krishfbt@iitr.ac.in
PH.: 091-1332-284779
Fax: 091-1332-273560

Figure S1: Effect of CIN and EUG on **(A)** *C. glabrata*, **(B)** CCG1, **(C)** CCG2, **(D)** CCG3 and **(E)** CCG4 biofilm development. The metabolic activity was measured by XTT reduction assay. Data is expressed in terms of percent inhibition of biofilm relative to its untreated control biofilm.



Figure S2: Effect of CIN and EUG in eradicating mature biofilm of **(A)** *C. glabrata*, **(B)** CCG1, **(C)** CCG2, **(D)** CCG3 and **(E)** CCG4. The metabolic activity was measured by XTT reduction assay. Data is expressed in terms of percent reduction of biofilm relative to its untreated control biofilm.



Figure S3: Quantification of hydrophobicity of *C. glabrata* and CCG3 cells treated with sub-inhibitory concentration of CIN (64 µg ml^{-1}), and EUG (128 µg ml^{-1}).



Table S1: Sequence of primers for RT-PCR

Primer	Sequence (5'-3')	Amplified product size (bp)
CgACT1-S CgACT1-AS	TTACCAACTGGGATGACATGGA GGAGCCTCGGTCAACAAGAC	145
CgCDR1-S CgCDR1-AS	AGATGTGTTGGTTCTGTCTCAAA CCGGAATACATTGACAAACCAAG	197
CgERG2-S CgERG2-AS	TCCCAGGTATGACCCATCATC TGCGAAGGAGTTTTGATCCAT	204
CgERG3-S CgERG3-AS	TGCACTGGCCTCGTGTCTAC TAACCGTCGACTGGGTGGAA	188
CgERG4-S CgERG4-AS	CCCTCAATTAGGTGTCGTCATGT GGCACGATTAATTCTTCACCCTTA	162
CgERG10-S CgERG10-AS	GCCAGAACCCCAATTGGTT TGCAATGACACCTAGGTCAACAG	195
CgERG11-S CgERG11-AS	TGTCTTGATGGGTGGTCAACA CTGGTCTTTCAGCCAAATGCA	184
CgAUS1-S CgAUS1-AS	TGGCTAACTTGTTCGCTGGT AGCGTACATTGCAGGGTTCA	125
CgKRE1-S CgKRE1-AS	CGAAGGCTACGACTACAAACA CGGCATCAGTGACAACAGTA	102
CgFKS1-S CgFKS1-AS	CGGTGATACAGCCAACTACAA CTCCTCCATGGCCTTCTTATTC	145

Table S2: Percentage reduction in metabolic activity of *C. glabrata* biofilm cells relative to control cells developed on the surface of urinary catheter and contact eye lens.

QQM (μg ml^{-1})	CG (% reduction in biofilm)		CCG 3 (% reduction in biofilm)	
	Catheter	Eye lens	Catheter	Eye lens
CIN (128)	36.1 ± 1.3	85.8± 1.7	76.9 ± 1.6	84.4± 1.1
CIN (256)	54.8 ± 3.8	86.7± 2.6	79.1± 1.5	84.8 ± 1.8
EUG (256)	14.4 ± 2.3	74.7± 2.7	57.1 ± 1.9	75.9 ± 1.3
EUG (512)	22.4 ± 3.5	83.7± 2.8	64.1± 1.2	79.4 ± 3.3